CStone Pharmaceuticals
A biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide.
Established in 2015, CStone has assembled a management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies.
As of Q4 2023, CStone has received 12 NDA approvals for its four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration.
Latest CStone Pharmaceuticals News & Features
31 May 2024
28 May 2024
15 March 2024
21 December 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze